Literature DB >> 33597306

Molecular mechanisms of assembly and TRIP13-mediated remodeling of the human Shieldin complex.

Wei Xie1, Shengliu Wang2, Juncheng Wang2, M Jason de la Cruz2, Guotai Xu3, Maurizio Scaltriti3, Dinshaw J Patel1.   

Abstract

The Shieldin complex, composed of REV7, SHLD1, SHLD2, and SHLD3, protects DNA double-strand breaks (DSBs) to promote nonhomologous end joining. The AAA+ ATPase TRIP13 remodels Shieldin to regulate DNA repair pathway choice. Here we report crystal structures of human SHLD3-REV7 binary and fused SHLD2-SHLD3-REV7 ternary complexes, revealing that assembly of Shieldin requires fused SHLD2-SHLD3 induced conformational heterodimerization of open (O-REV7) and closed (C-REV7) forms of REV7. We also report the cryogenic electron microscopy (cryo-EM) structures of the ATPγS-bound fused SHLD2-SHLD3-REV7-TRIP13 complexes, uncovering the principles underlying the TRIP13-mediated disassembly mechanism of the Shieldin complex. We demonstrate that the N terminus of REV7 inserts into the central channel of TRIP13, setting the stage for pulling the unfolded N-terminal peptide of C-REV7 through the central TRIP13 hexameric channel. The primary interface involves contacts between the safety-belt segment of C-REV7 and a conserved and negatively charged loop of TRIP13. This process is mediated by ATP hydrolysis-triggered rotatory motions of the TRIP13 ATPase, thereby resulting in the disassembly of the Shieldin complex.
Copyright © 2021 the Author(s). Published by PNAS.

Entities:  

Keywords:  SHLD2–SHLD3–REV7 complex; SHLD2–SHLD3–REV7–TRIP13 complex; SHLD3–REV7 complex; Shieldin assembly; TRIP13-mediated disassembly of Shieldin

Year:  2021        PMID: 33597306      PMCID: PMC7923543          DOI: 10.1073/pnas.2024512118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  Rev7 dimerization is important for assembly and function of the Rev1/Polζ translesion synthesis complex.

Authors:  Alessandro A Rizzo; Faye-Marie Vassel; Nimrat Chatterjee; Sanjay D'Souza; Yunfeng Li; Bing Hao; Michael T Hemann; Graham C Walker; Dmitry M Korzhnev
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-15       Impact factor: 11.205

2.  Structural basis of recruitment of DNA polymerase ζ by interaction between REV1 and REV7 proteins.

Authors:  Sotaro Kikuchi; Kodai Hara; Toshiyuki Shimizu; Mamoru Sato; Hiroshi Hashimoto
Journal:  J Biol Chem       Date:  2012-08-02       Impact factor: 5.157

3.  MAD2B is an inhibitor of the anaphase-promoting complex.

Authors:  J Chen; G Fang
Journal:  Genes Dev       Date:  2001-07-15       Impact factor: 11.361

4.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

5.  Dynamic feature of mitotic arrest deficient 2-like protein 2 (MAD2L2) and structural basis for its interaction with chromosome alignment-maintaining phosphoprotein (CAMP).

Authors:  Kodai Hara; Shota Taharazako; Masanori Ikeda; Hiroki Fujita; Yoshiko Mikami; Sotaro Kikuchi; Asami Hishiki; Hideshi Yokoyama; Yoshinobu Ishikawa; Shin-Ichiro Kanno; Kozo Tanaka; Hiroshi Hashimoto
Journal:  J Biol Chem       Date:  2017-09-08       Impact factor: 5.157

6.  FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1-defective cells.

Authors:  Junya Tomida; Kei-Ichi Takata; Sarita Bhetawal; Maria D Person; Hsueh-Ping Chao; Dean G Tang; Richard D Wood
Journal:  EMBO J       Date:  2018-05-22       Impact factor: 11.598

Review 7.  Moving Mountains-The BRCA1 Promotion of DNA Resection.

Authors:  Ruth M Densham; Joanna R Morris
Journal:  Front Mol Biosci       Date:  2019-09-03

8.  Disassembly of the Shieldin Complex by TRIP13.

Authors:  Prabha Sarangi; Connor S Clairmont; Alan D D'Andrea
Journal:  Cell Cycle       Date:  2020-05-18       Impact factor: 4.534

Review 9.  The multifaceted roles of the HORMA domain in cellular signaling.

Authors:  Scott C Rosenberg; Kevin D Corbett
Journal:  J Cell Biol       Date:  2015-11-23       Impact factor: 10.539

10.  The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

Authors:  Marco Barazas; Stefano Annunziato; Stephen J Pettitt; Inge de Krijger; Hind Ghezraoui; Stefan J Roobol; Catrin Lutz; Jessica Frankum; Fei Fei Song; Rachel Brough; Bastiaan Evers; Ewa Gogola; Jinhyuk Bhin; Marieke van de Ven; Dik C van Gent; Jacqueline J L Jacobs; Ross Chapman; Christopher J Lord; Jos Jonkers; Sven Rottenberg
Journal:  Cell Rep       Date:  2018-05-15       Impact factor: 9.423

View more
  6 in total

Review 1.  Functions and Regulation of Meiotic HORMA-Domain Proteins.

Authors:  Josh P Prince; Enrique Martinez-Perez
Journal:  Genes (Basel)       Date:  2022-04-27       Impact factor: 4.141

Review 2.  REV7 directs DNA repair pathway choice.

Authors:  Connor S Clairmont; Alan D D'Andrea
Journal:  Trends Cell Biol       Date:  2021-06-16       Impact factor: 20.808

Review 3.  REV7: Jack of many trades.

Authors:  Inge de Krijger; Vera Boersma; Jacqueline J L Jacobs
Journal:  Trends Cell Biol       Date:  2021-05-04       Impact factor: 20.808

4.  DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity.

Authors:  Taketsugu Hama; Prashanth Kb Nagesh; Pallabita Chowdhury; Bob M Moore; Murali M Yallapu; Kevin R Regner; Frank Park
Journal:  JCI Insight       Date:  2021-11-22

5.  Disrupting the MAD2L2-Rev1 Complex Enhances Cell Death upon DNA Damage.

Authors:  Nomi Pernicone; Maria Elias; Itay Onn; Dror Tobi; Tamar Listovsky
Journal:  Molecules       Date:  2022-01-19       Impact factor: 4.411

6.  DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.

Authors:  Sumit Agarwal; Farrukh Afaq; Prachi Bajpai; Hyung-Gyoon Kim; Amr Elkholy; Michael Behring; Darshan Shimoga Chandrashekar; Sameer Al Diffalha; Moh'd Khushman; Shajan P Sugandha; Sooryanarayana Varambally; Upender Manne
Journal:  Mol Oncol       Date:  2022-03-07       Impact factor: 7.449

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.